Blood Test May Replace Brain Scans for Alzheimer's Early Detection
DiamiR and AlzLabs are combining protein biomarkers with microRNA signatures to match PET scan accuracy using a simple blood draw.
Summary
A new collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics aims to validate blood-based biomarkers for Alzheimer's disease detection. The study examines whether markers like p-Tau 217, amyloid 42/40, and neurofilament light (NfL) in blood plasma can deliver results comparable to amyloid PET scans — currently the gold standard but expensive and inaccessible to many. DiamiR's proprietary CogniMIR platform adds microRNA analysis to the mix, potentially offering a richer biological picture of brain changes. The collaboration coincides with the upcoming merger of Aptorum and DiamiR into Niki BioSolutions, signaling serious ambitions in neurodiagnostics ahead of fiscal 2027.
Detailed Summary
Alzheimer's disease silently reshapes the brain for years before symptoms emerge, yet confirming its presence typically requires costly amyloid PET imaging unavailable to much of the world. A new research collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics is directly challenging that dependency by asking whether a blood test can tell the same story as an expensive brain scan.
The study will measure key Alzheimer's blood biomarkers — including p-Tau 217, amyloid 42/40, and neurofilament light (NfL) — in plasma samples from participants whose amyloid status has already been confirmed via PET imaging. This head-to-head design allows researchers to rigorously assess how well blood signals mirror established imaging findings, providing a clear validation framework rather than exploratory guesswork.
What distinguishes DiamiR's approach is the addition of its CogniMIR microRNA platform alongside conventional protein markers. MicroRNAs regulate gene expression and may carry organ-specific biological signals, including those originating in the brain. By layering microRNA data onto standard biomarkers, the team hopes to capture a more complete picture of neurodegeneration — reflecting precision medicine's shift away from single-marker diagnostics toward multi-signal panels.
The collaboration arrives weeks after shareholders approved the merger of Aptorum Group and DiamiR into a new entity called Niki BioSolutions, expected to close before fiscal 2027. This timing suggests the AlzLabs partnership may be a strategic move to establish credibility and data assets in neurodiagnostics ahead of the new company's launch.
Caveats remain significant. The study is still in early stages, with no published results yet. Validating a blood test against PET imaging is a necessary but not sufficient step toward clinical adoption, which requires regulatory approval, large-scale trials, and real-world performance data. Still, for health-conscious adults watching Alzheimer's diagnostics evolve, this collaboration represents a meaningful step toward accessible, early detection.
Key Findings
- Blood biomarkers p-Tau 217, amyloid 42/40, and NfL are being validated against gold-standard amyloid PET imaging.
- DiamiR's CogniMIR platform adds microRNA signatures to protein markers for potentially more accurate Alzheimer's assessment.
- Multi-biomarker panels may outperform single-marker tests in detecting complex, slowly progressing neurodegeneration.
- The DiamiR–AlzLabs collaboration precedes the Aptorum–DiamiR merger into Niki BioSolutions, expected before fiscal 2027.
- Accessible blood-based Alzheimer's diagnostics could dramatically expand early detection beyond specialized imaging centers.
Methodology
This is a news report summarizing a corporate research collaboration announcement, not a peer-reviewed study. The source, Longevity.Technology, is a specialist industry publication with reasonable credibility in biotech reporting. No primary data or published results are available yet; evidence basis is limited to company statements and study design descriptions.
Study Limitations
No study results have been published; all findings are anticipated rather than demonstrated. The collaboration is industry-sponsored, introducing potential bias in how results are reported. Regulatory approval and large-scale validation trials are still required before any blood test could replace or supplement PET imaging in clinical practice.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: